Form 424B5 Wave Life Sciences Ltd.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)
September 25, 2024 6:24 AM EDTB.Riley analyst Madison El-Saadi reiterated a Buy rating and $11.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "In totality, we believe results exceeded our/investor expectations (9/18 initiation) and replicated the preclinical and early clinical datasets indicative of best-in-class exon skipping profile... More
WAVE Life Sciences (WVE) no longer intends to offers ordinary shares
September 24, 2024 5:23 PM EDTWAVE Life Sciences (NASDAQ: WVE) has filed the following prospectus:
This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 4, 2022 (the Prospectus), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $131,974,010 (the Maximum Offering Amount) of our... More
